Blueprint Medicines (BPMC) Reports Q2 Loss of $0.62/Share
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Join SI Premium – FREE
Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($0.62), versus ($0.86) reported last year. Revenue for the quarter came in at $41.44 million, versus $5.89 million reported last year.
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HP shares slide as tech giant forecasts 2027 PC market slump
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- Evercore lifts Ciena rating on AI-driven optical networking boom
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
